7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management.

Slides:

Advertisements

Similar presentations

Improving diagnosis TB laboratory strengthening.

Advertisements

Sevene E, Mariano A, Mola D Faculty of Medicine / Ministry of Health Pretoria, September 2004 PHARMACOVIGILANCE SYSTEM - MOZAMBIQUE INTRODUCING PV INTO.

Monitoring and Evaluation Frameworks   What is an M&E Framework?   Why do we use M&E Frameworks?   How do we develop M&E Frameworks? MEASURE Evaluation.

Safety and Vigilance (SAV)

Manila, Dec.2014 NEW DRUGS INTRODUCTION IN VIETNAM – SHORT PROGRESS UPDATE.

World Tuberculosis Day 2014 The TB situation in 2012: Findings from the joint TB surveillance and monitoring report by ECDC and the WHO Regional Office.

Pharmacovigilance in Kenya Dr. Dorine Kagai (NASCOP) Mr. George Muthuri (PPB) Ministry of Medical Services 23 nd November, 2009 ARV PV TRAINING TZ.

Pharmacovigilance Programme of India

1 TYSABRI Risk Management Plan Will Maier, PhD Senior Director, Epidemiology.

Monitoring and Evaluation Module 12 – March 2010.

PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.

Sten Olsson WHO Programme Expert Uppsala Monitoring Centre Sweden

1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.

METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.

A Method for Mining Infrequent Causal Associations and Its Application in Finding Adverse Drug Reaction Signal Pairs.

Training course on the Pharmacovigilance of antiretroviral medicines 23 – 28 November 2009 Rationale, Objectives and Expected Outcomes.

FDA Risk Management Workshop – Day #3 April 11, 2003 Robert C. Nelson, Ph.D. RCN Associates, Inc Annapolis, MD, USA.

KNCV experience with PV/aDSM Symposium 12 Suzanne Verver, Agnes Gebhard, Susan van den Hof, Gunta Dravniece, Svetlana Pak, Sandra Kik.

Dr Mary Couper Quality Assurance and Safety of Medicines WHO

Monitoring Activities Answer the Following Questions: What is being done? Scope How well is it being done? Quality Are we doing it on a large enough scale?

Minimum requirements for Pharmacovigilance in countries.

European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.

PHARMACOVIGILANCE PLAN FOR TANZANIA PREPARED BY EMMA & MARY 10 TH SEPTEMBER 2004.

Feasibility of establishing PVC in the Ugandan health system By Juliet & Martin September 2004.

Core Topic 11 Documentation, record keeping and reporting.

World Tuberculosis Day 2016 Monitoring the implementation of the Framework Action Plan to Fight Tuberculosis in the European Union – Situation in 2014.

6. Records Management & Quality Assurance of Data

11 iv. Create standard data collection materials

Detection & monitoring of ADR

Overview of the EAC Pharmacovigilance and Post-Marketing Surveillance Systems 1ST International High Level Multi-Stakeholder Conference Nairobi, 2-4.

11 v. Train staff on the collection of data

Monitoring and Evaluation Frameworks

11 vi. Define schedules and routes for data collection and reporting

5. National and international reporting of adverse events: mechanisms, routes and resources Multi-partner training package on active TB drug safety monitoring.

World Tuberculosis Day 2014

11 vii. Consolidate aDSM data electronically

EudraVigilance.

8. Causality assessment:

11 viii. Develop capacity for signal detection and causality assessment Multi-partner training package on active TB drug safety monitoring and management.

11 ii. Develop a plan for aDSM

1. Structure and training objectives for this course & key references

12. Role of national and international technical and funding partners in the implementation of aDSM Multi-partner training package on active TB drug safety.

2. Active TB drug-safety monitoring : rationale and mechanisms in the context of TB & MDR-TB treatment Multi-partner training package on active TB drug.

Strengthening systems for safety monitoring for SMC in the Sahel

11 i. Create a national coordinating mechanism for aDSM

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

Pharmacovigilance in clinical trials

10. Overview on risk communication and new knowledge integration

عناوین برنامه واهداف ADR ونقش آن در ایمنی دارویی محاسبات دارویی

9. Introduction to signal detection

Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.

Helen Lee, European Commission

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

Medicines safety in WHO: promoting best practices in Pharmacovigilance

68.3 million errors (28% of total) cause moderate or serious harm

Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.

EPSO Risk profile working group

Dr. Evelyn Muthoni Karanja WHO ARV guidelines satellite

World Tuberculosis Day 2016

World Tuberculosis Day 2014

Session 4: Expanded indications for bedaquiline and delamanid

Christine Halleux, MD, PhD

Pharmacovigilance Systems: Drug Safety Surveillance

5th DEWG meeting Conclusions

monitoring & evaluation THD Unit, Stop TB department WHO Geneva

11 iii. Define management and supervision roles and responsibilities

TB SUREVEILLANCE MEETING: OBJECTIVES

Issues on the current information system

The ACCORD Study Group. NEJM 2010; Epub March 14

Background & rational DEWG meeting 2009

Presentation transcript:

7. aDSM slides - Indicators of aDSM implementation and programme management Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016

Learning objectives By the end of this presentation, the participant is expected to be able to… Define the standard aDSM indicators for programme management

aDSM data serve a number of purposes aDSM indicators (1) aDSM data serve a number of purposes Programme indicators Causality assessment Signal detection Drug-safety profiles

aDSM indicators (2) The programme manager needs measures of process and outcomes, especially in the early phases of implementing aDSM This is besides the analyses needed for causality assessment and signal detection Five indicators have been proposed to assess coverage and completeness of reporting, and the frequency of SAEs and confirmed ADRs

aDSM indicators (3) summary Class Indicator Coverage MDR-TB patients on BDQ included in active PV Completeness Time to stopping BDQ Serious adverse events MDR-TB patients included in cohort event monitoring with any serious adverse event BDQ-associated adverse reactions Frequency of BDQ-associated ADRs Time to development of BDQ-associated ADRs

aDSM indicators (4)

aDSM indicators (5)

aDSM indicators (6)

Table 11.5

WHO/HTM/TB/2014.09 This book presents the practicalities of standard and advanced analysis of programme TB surveillance data. The same approaches could have an application for in-depth analysis of aDSM data. apps.who.int/iris/bitstream/10665/129942/1/9789241548786_eng.pdf